Targets › TYK2
16 programs from 15 companies in 202 trials: 85 Phase 2, 52 Phase 3, 42 Phase 1, 23 Phase 4; Immunology, Other, Oncology; next expected readout Nov 2026.
Non-membrane spanning protein tyrosine kinase involved in numerous cytokines and interferons signaling, which regulates cell growth, development, cell migration, innate and adaptive immunity. Plays both structural and catalytic roles in numerous interleukins and interferons (IFN-alpha/beta) signaling. (UniProt, P29597)
Open in Phaseline: the race on TYK2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | Deucravacitinib Tyrosine-protein kinase TYK2 negative allosteric modulator | TYK2 | Phase 4 | Systemic Lupus Erythematosus (SLE); Psoriatic Arthritis; Sjögren's Syndrome; Systemic Lupus Erythematosus … | Nov 2026 |
| Takeda | Tofacitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 4 | Ulcerative Colitis; Rheumatoid Arthritis; Axial Spondyloarthritis; Oral Lichen Planus … | Jul 2027 |
| Eisai | Filgotinib Maleate Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor | JAK1, JAK2, TYK2, JAK3 | Phase 4 | Ulcerative Colitis | Nov 2027 |
| Incyte | Ruxolitinib Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 3 | NonSegmental Vitiligo; Hidradenitis Suppurativa; Atopic Dermatitis; Graft-versus-host Disease (GVHD) … | Nov 2026 |
| AbbVie | Upadacitinib Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor | TYK2, JAK3, JAK2, JAK1 | Phase 3 | Atopic Dermatitis; Systemic Lupus Erythematosus; Ulcerative Colitis (UC); Crohn's Disease … | Nov 2026 |
| InventisBio | [14C] D-2570 TYK2 pseudokinase domain inhibitor | TYK2 | Phase 3 | Plaque Psoriasis; UC - Ulcerative Colitis; Psoriasis; PsA (Psoriatic Arthritis) … | Nov 2026 |
| LEO Pharma | Delgocitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 3 | Lichen Sclerosus; Palmoplantar Pustulosis; Central Centrifugal Cicatricial Alopecia; Vitiligo | Dec 2026 |
| Pfizer | tofacitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 3 | Ulcerative Colitis | Mar 2027 |
| Sun Pharmaceutical Industries | Deuruxolitinib Phosphate (CTP-543) Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 3 | Alopecia Areata | May 2027 |
| Alfasigma | Filgotinib Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor | JAK1, JAK2, TYK2, JAK3 | Phase 3 | Polyarticular Course Juvenile Idiopathic Arthritis; Juvenile Idiopathic Arthritis (JIA); Ulcerative Colitis; Axial Spondyloarthritis … | Jun 2027 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | TQH3906 Capsules Highly selective TYK2 allosteric inhibitor targeting the JH2 domain, blocking IL-23 and Ty | TYK2 | Phase 3 | Psoriasis; Psoriatic Arthritis; Inflammatory Bowel Diseases | Jul 2027 |
| Alumis | Envudeucitinib (ESK-001) Oral PROTAC degrader of Ikaros (IKZF1) | IKZF1, TYK2 | Phase 3 | Plaque Psoriasis; SLE | Sep 2027 |
| M.D. Anderson Cancer Center | Ruxolitinib Phosphate Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 2 | Splenomegaly; AML; Chronic Lymphocytic Leukemia; T-cell Prolymphocytic Leukemia … | Jan 2027 |
| City of Hope Medical Center | Ruxolitinib Phosphate Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 2 | Acute Lymphoblastic Leukemia; Follicular Helper T-Cell Lymphoma; Hematopoietic and Lymphatic System Neoplasm | Mar 2027 |
| Shixiu Wu | JAK Inhibitors Janus kinase inhibitors | JAK1, JAK2, JAK3, TYK2 | Phase 2 | Immune Checkpoint Inhibitors (ICI)-Related Dermatitis | – |
| AbbVie | Tofacitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 1 | Healthy Volunteers | Dec 2026 |
Plaque Psoriasis (7) Ulcerative Colitis (6) Rheumatoid Arthritis (6) Atopic Dermatitis (6) Vitiligo (5) Alopecia Areata (4) Hidradenitis Suppurativa (4) Acute Lymphoblastic Leukemia (4) Psoriatic Arthritis (3) Systemic Lupus Erythematosus (3) Psoriasis (3) Rheumatoid Arthritis (RA (3)
small molecule (15), mixed (1)
AbbVie (2) Sun Pharmaceutical Industries (1) Alumis (1) Bristol-Myers Squibb (1) Alfasigma (1) Takeda (1) Incyte (1) LEO Pharma (1) Eisai (1) InventisBio (1) City of Hope Medical Center (1) Shixiu Wu (1) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical (1) M.D. Anderson Cancer Center (1) Pfizer (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.